ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Amgen’s Blincyto gets US approval for acute lymphoblastic leukaemia
April 09, 2018Amgen has received approval from the US Food and Drug Administration (FDA) for Blincyto, a drug to treat B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children. -
FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse
March 30, 2018FDA granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD) -
Amgen’s Blincyto wins full US approval
July 17, 2017Amgen’s Blincyto has been issued a full approval in the US as a treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Pharma Sources Insight January 2025
